Paper92181
Virus augmentation of the antigenicity of tumor cell extracts.
Austin FC and 1 other. Adv Cancer Res, 1979. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. Virus augmentation of the antigenicity of tumor cell extracts. Papers, record 92181. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/92181
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Neoplasm | Major topic |
| Antigens, Neoplasm | Major topic |
| Antigens, Viral | Major topic |
| Histocompatibility Antigens | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Antibodies, Viral | |
| Epitopes | |
| Humans | |
| Immunotherapy | |
| Mice | |
| Rats |
Source PubMed
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 30061941 | Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells. | Oncol Lett | 2018 | https://conductscience.org/library/papers/30061941 | PubMed |
| 24833054 | Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. | Biology (Basel) | 2013 | https://conductscience.org/library/papers/24833054 | PubMed |
| 20356763 | Whole tumor antigen vaccines. | Semin Immunol | 2010 | https://conductscience.org/library/papers/20356763 | PubMed |
| 10341877 | Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. | Gene Ther | 1999 | https://conductscience.org/library/papers/10341877 | PubMed |
| 7728569 | Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. | Ann Surg Oncol | 1995 | https://conductscience.org/library/papers/7728569 | PubMed |
| 6985248 | Antigenic variation in cancer metastasis: immune escape versus immune control. | Cancer Metastasis Rev | 1982 | https://conductscience.org/library/papers/6985248 | PubMed |
| 6607104 | Immune responses of DBA/2 mice bearing melanoma tumors: cell-mediated immune responses after challenge with vaccinia virus. | Cancer Immunol Immunother | 1983 | https://conductscience.org/library/papers/6607104 | PubMed |
| 6299231 | Susceptibility of Marek's disease lymphoblastoid cell lines to infection with influenza and pseudorabies viruses and the protective effect of immunization with influenza virus-infected lymphoblastoid cells. | Arch Virol | 1982 | https://conductscience.org/library/papers/6299231 | PubMed |
| 6265347 | Sendai virus infected cells are readily cytolysed by guinea-pig complement without antibody. | Immunology | 1981 | https://conductscience.org/library/papers/6265347 | PubMed |
| 6203637 | Immune recognition of tumor cells in mice infected with Pichinde virus. | Cancer Immunol Immunother | 1984 | https://conductscience.org/library/papers/6203637 | PubMed |
| 6088033 | Virus-augmented delayed hypersensitivity skin tests in gynecological malignancies. | Cancer Immunol Immunother | 1984 | https://conductscience.org/library/papers/6088033 | PubMed |
| 3677126 | Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. | Cancer Immunol Immunother | 1987 | https://conductscience.org/library/papers/3677126 | PubMed |
| 3460702 | Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients. | Cancer Immunol Immunother | 1986 | https://conductscience.org/library/papers/3460702 | PubMed |
| 3359458 | Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia. | Cancer Immunol Immunother | 1988 | https://conductscience.org/library/papers/3359458 | PubMed |
| 3297373 | Chemical xenogenization of experimental tumors. | Cancer Metastasis Rev | 1987 | https://conductscience.org/library/papers/3297373 | PubMed |
| 2598179 | Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2598179 | PubMed |
| 2462467 | Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2462467 | PubMed |
| 2225567 | Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity. | Clin Exp Metastasis | 1990 | https://conductscience.org/library/papers/2225567 | PubMed |
| 1561807 | Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. | World J Surg | 1992 | https://conductscience.org/library/papers/1561807 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/92181
GET https://conductscience.org/api/papers/v1/92181/authors